
A NAACOS and Innovaccer survey of 116 leaders also found only 21% are tracking which of their patients have enrolled in the new chronic care model.
Older patients started on oral antidiabetic therapy with a sulfonylurea have significantly higher risk for cardiovascular disease (CVD) events than patients started on metformin.





